Skip to content

The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)

The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030020
Enrollment
Unknown
Registered
2020-02-20
Start date
2020-02-06
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Second Hospital of University of South China, Hengyang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-70 years (2) Clinical symptoms, signs, and lung CT suggest changes in lung inflammation. Patients diagnosed with new type of coronavirus pneumonia combined with more than one nucleic acid test (3) Clinical symptoms, signs, and lung CT suggest lung inflammation changes. Combined with more than one respiratory or blood specimen virus gene sequencing, it is highly homologous to known new coronaviruses. (4) Negative nucleic acid or viral gene test, but New Crown Pneumonia expert group discusses cases with high suspicion of New Crown Pneumonia (5) Voluntarily sign the informed consent and agree to comply with the requirements of the test protocol (6) Patients can communicate in words or words. Sign informed consent (7) The patient agrees and has the ability to complete auxiliary tests related to the trial

Exclusion criteria

Exclusion criteria: (1) Subject has a history of tumor (2) Female patients of childbearing age during pregnancy, lactation or recent birth planning (3) Highly allergic constitution or history of severe allergies (4) Coagulation disorders such as hemophilia (5) Those with positive serological tests such as AIDS, syphilis, etc. (6) Patients who have participated in or are participating in other drug trials within one month (7) Patients who the investigator refused to participate in this clinical trial (8) There is a large area of pulmonary vascular embolism and severe pulmonary hypertension

Design outcomes

Primary

MeasureTime frame
Coronavirus nucleic acid markers negative rate;Symptoms improved after 4 treatments;Inflammation (CT of the chest);

Secondary

MeasureTime frame
Trough and peak of pulmonary function FEV1;Lymphocyte subpopulation changes;

Countries

China

Contacts

Public ContactLuo Zhigang

Second Hospital of University of South China, Hengyang

706885399@qq.com+86 13907342350

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026